Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
ASH 2024 preview – CD19 back on the agenda
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
